Navigation Links
Aviir Laboratories Announce National Agreement with Three Rivers Provider Network
Date:5/7/2012

IRVINE, Calif., May 7, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostics laboratory testing as a participating provider with TRPN and its 10 million lives network.

Three Rivers Provider Network (TRPN) was founded in 1996 as a company that was contracted to provide services for several major clients. At that time, its clients needed to access a network that would grant PPO type discounts without incurring balance billing risks for their members. Over time, given superior results and the high levels of satisfaction of service that were achieved, TRPN was prompted by other companies that focused on group health and workers compensation to perform similar type services for them.  

Since that time, TRPN has evolved into the largest and fastest growing proprietary PPO network in the United States. The TRPN network is now comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities. Through its clients, approximately 10 million lives now have access to the TRPN PPO network.

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients who are truly at high risk for the development of a cardiac event.  Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.  Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reducing their risk of heart attacks, and decreasing the overall cost of care," Dr. Harrington added.

Learn more at www.aviir.com
Learn more at www.trpnppo.com

For more information:
Dina Scaglione
Marketing, Communications Manager
Dina.Scaglione@aviir.com

 


'/>"/>
SOURCE Aviir Diagnostic Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. Aviir Laboratories Announce National Agreement With MultiPlan
3. AIT Laboratories Expands Pharma Services
4. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
5. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
6. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
7. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
8. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
9. Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
10. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
11. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
(Date:1/18/2017)... HACKENSACK, N.J. , Jan. 18, 2017   ... leading the fight to end Duchenne muscular dystrophy ... awarded to the New Jersey Institute of Technology (NJIT) ... ongoing exploration of robotic technology to assist ... study to incorporate NJIT,s technology – an embedded computer, ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and Sports ... A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at Long ... an anterior cervical discectomy and fusion on a 42 year old female who ...
(Date:1/18/2017)... ... January 18, 2017 , ... Announced in December ... Institutes (MII). U.S. Secretary of Commerce Penny Pritzker has announced the award of ... of Defense has announced the award of a new Advanced Regenerative Manufacturing Institute ...
Breaking Biology Technology:
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
Breaking Biology News(10 mins):